Page last updated: 2024-11-05

tulobuterol and Asthma

tulobuterol has been researched along with Asthma in 41 studies

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"Compared with oral salbutamol sulfate, tulobuterol patch has a better therapeutic efficacy and a higher safety in children with mild or moderate acute asthmatic attack."9.17[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013)
"Tulobuterol patch (Tulo) is often used for treatment of elder patient with asthma in Japan."9.16[Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment]. ( Haruta, Y; Kondoh, K; Mukaida, K; Onari, Y, 2012)
"Whether the additive effects of the tulobuterol patch (TP), the world's first transdermal beta2-agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear."9.14Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. ( Haruta, Y; Hozawa, S; Terada, M; Yamakido, M, 2009)
"Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy."9.12Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006)
"Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study."9.12Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007)
"To evaluate the efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients."9.12[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]. ( Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007)
"In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC."9.06Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986)
"The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients."9.06Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988)
"Fifteen asthmatic patients participated in a dose-ranging study using tulobuterol syrup in single doses of 10 to 60 mcg/kg."9.06Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies. ( Javier, MA; Noche, ML, 1986)
"Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported."7.78[Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes]. ( Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012)
"We investigated the efficacy of nighttime transdermal tulobuterol (beta2-adrenoceptor agonist) chronotherapy for nocturnal asthma by assessing changes both in the frequency of symptoms and features of the circadian rhythm in peak expiratory flow (PEF), a measure of airway caliber."7.73Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. ( Burioka, N; Endo, M; Fukuoka, Y; Igawa, K; Miyata, M; Nakazaki, H; Shimizu, E; Suyama, H, 2005)
"We report the pharmacokinetics and pharmacodynamics of tulobuterol patch, HN-078, in the treatment of childhood asthma."7.69Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ( Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995)
" Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax."6.41[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. ( Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002)
"Bronchial asthma is a chronic disease which is currently treated using various inhalants."5.62Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma. ( Chen, Y; Jin, S; Luo, L; Luo, S; Wu, B; Xu, C; Yang, T, 2021)
"We suggest that this treatment of bronchial asthma may protect against endotoxin contained in inhaled house dust."5.35Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. ( Miura, M; Murakami, Y; Nishio, T; Sasaki, K; Shindoh, C; Shishido, R, 2009)
"2."5.31Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. ( Ito, Y; Kondo, M; Kume, H; Suzuki, R; Takagi, K; Yamaki, K, 2002)
"Compared with oral salbutamol sulfate, tulobuterol patch has a better therapeutic efficacy and a higher safety in children with mild or moderate acute asthmatic attack."5.17[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013)
"Tulobuterol patch (Tulo) is often used for treatment of elder patient with asthma in Japan."5.16[Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment]. ( Haruta, Y; Kondoh, K; Mukaida, K; Onari, Y, 2012)
"Whether the additive effects of the tulobuterol patch (TP), the world's first transdermal beta2-agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear."5.14Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. ( Haruta, Y; Hozawa, S; Terada, M; Yamakido, M, 2009)
"Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy."5.12Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006)
"To evaluate the efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients."5.12[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]. ( Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007)
"Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study."5.12Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007)
"Fifteen asthmatic patients participated in a dose-ranging study using tulobuterol syrup in single doses of 10 to 60 mcg/kg."5.06Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies. ( Javier, MA; Noche, ML, 1986)
"The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients."5.06Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988)
"In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC."5.06Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986)
"Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported."3.78[Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes]. ( Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012)
"Tulobuterol patches are long-acting bronchodilators for percutaneous absorption including the β(2)-adrenoreceptor agonist tulobuterol, as a main ingredient, used for long-term management of pediatric asthma."3.76Comparative study of skin permeation profiles between brand and generic tulobuterol patches. ( Abe, T; Arisaka, O; Fukuda, H; Yoshihara, S, 2010)
"We investigated the efficacy of nighttime transdermal tulobuterol (beta2-adrenoceptor agonist) chronotherapy for nocturnal asthma by assessing changes both in the frequency of symptoms and features of the circadian rhythm in peak expiratory flow (PEF), a measure of airway caliber."3.73Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. ( Burioka, N; Endo, M; Fukuoka, Y; Igawa, K; Miyata, M; Nakazaki, H; Shimizu, E; Suyama, H, 2005)
"We report the pharmacokinetics and pharmacodynamics of tulobuterol patch, HN-078, in the treatment of childhood asthma."3.69Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ( Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995)
"Tulobuterol is a synthetic beta-adrenergic agonist which, when administered orally, is a potent, long-acting bronchodilator."2.67Can a new beta 2-agonist reduce the mortality of asthma? ( Aldons, PM, 1990)
"Tulobuterol is a new synthetic beta 2-agonist with potent and prolonged bronchodilator activity when given by oral and inhaled routes."2.67Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis. ( Patel, KR, 1990)
" Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax."2.41[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. ( Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002)
" When chronic symptoms necessitate maintenance treatment, the frequency of dosing may become a deciding factor in the selection of a bronchodilator."2.37Tulobuterol in the management of obstructive airways disease in adults. ( Patel, KR, 1985)
"Bronchial asthma is a chronic disease which is currently treated using various inhalants."1.62Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma. ( Chen, Y; Jin, S; Luo, L; Luo, S; Wu, B; Xu, C; Yang, T, 2021)
"Persistent cough is a frequent cause of doctor and hospital visits, and its incidence may be increasing."1.39Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan. ( Adachi, M; Akiyama, K; Hasegawa, M; Inoue, H; Kimura, G; Kobayashi, H; Niimi, A; Ohbayashi, H; Sagara, H; Takahashi, K; Wakayama, T; Yamauchi, K; Yokoe, T, 2013)
"We suggest that this treatment of bronchial asthma may protect against endotoxin contained in inhaled house dust."1.35Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. ( Miura, M; Murakami, Y; Nishio, T; Sasaki, K; Shindoh, C; Shishido, R, 2009)
"2."1.31Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. ( Ito, Y; Kondo, M; Kume, H; Suzuki, R; Takagi, K; Yamaki, K, 2002)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-19909 (21.95)18.7374
1990's5 (12.20)18.2507
2000's17 (41.46)29.6817
2010's9 (21.95)24.3611
2020's1 (2.44)2.80

Authors

AuthorsStudies
Luo, S1
Jin, S1
Yang, T1
Wu, B1
Xu, C1
Luo, L1
Chen, Y1
Hong, JG1
Li, Z1
Lin, Q1
Liu, QH1
Bao, YX1
Niimi, A2
Ohbayashi, H1
Sagara, H1
Yamauchi, K1
Akiyama, K2
Takahashi, K1
Inoue, H2
Wakayama, T1
Kobayashi, H1
Hasegawa, M1
Kimura, G1
Yokoe, T1
Adachi, M2
Matsumoto, H1
Ito, I1
Oguma, T1
Otsuka, K1
Takeda, T1
Nakaji, H1
Tajiri, T1
Iwata, T1
Nagasaki, T1
Mishima, M1
Shindoh, C1
Murakami, Y1
Shishido, R1
Sasaki, K1
Nishio, T1
Miura, M1
Hozawa, S1
Haruta, Y2
Terada, M1
Yamakido, M1
Yoshihara, S2
Fukuda, H1
Abe, T2
Arisaka, O2
Tamura, G3
Ichinose, M1
Fukuchi, Y1
Miyamoto, T1
Izumi, T1
Hori, S1
Satoh, H1
Miki, A1
Sawada, Y1
Onari, Y1
Mukaida, K1
Kondoh, K1
Katsunuma, T1
Fujisawa, T1
Nagao, M1
Akasawa, A1
Nomura, I1
Yamaoka, A1
Kondo, H1
Masuda, K1
Yamaguchi, K1
Terada, A1
Ikeda, M1
Nishioka, K1
Adachi, Y1
Kurihara, K1
Kume, H2
Kondo, M1
Ito, Y1
Suzuki, R1
Yamaki, K1
Takagi, K1
Tsurikisawa, N1
Taniguchi, M1
Suzuki, S1
Horiguchi, T2
Kondo, R2
Miyazaki, J2
Torigoe, H2
Tachikawa, S1
Fukumokto, K1
Burioka, N1
Miyata, M1
Endo, M1
Fukuoka, Y1
Suyama, H1
Nakazaki, H1
Igawa, K1
Shimizu, E1
Yamada, Y1
Fujimoto, K1
Komatsu, Y1
Yasuo, M1
Urushihata, K1
Kubo, K1
Nishiyama, O1
Taniguchi, H1
Kondoh, Y1
Kimura, T1
Kato, K1
Shimokata, K1
Su, N1
Lin, JT1
Yang, M1
Chen, X1
He, J1
He, QY1
Cao, ZL1
Chen, BY1
Xiao, Y1
Yan, XX1
Kobayashi, Y1
Yasuba, H1
Kudou, M1
Kita, H1
Mita, S1
Takahashi, T1
Iikura, Y1
Uchiyama, H1
Akimoto, K1
Ebisawa, M1
Sakaguchi, N1
Tsubaki, T1
Ishizu, H1
Kabayama, H1
Yagi, K1
Miura, K1
Fujimori, K1
Suzuki, E1
Gejyo, F1
Ojima, F1
Nakamura, H1
Ebihara, M1
Shoji, T1
Tomike, H1
Nakagawa, Y1
Numao, T1
Fukuda, T1
Kato, H1
Nagata, O1
Yamazaki, M1
Suzuki, T1
Nakano, Y1
Aldons, PM1
Rühle, KH1
Dorow, P1
Schmitz-Schumann, H1
Patel, KR4
Tomioka, S1
Kuroiwa, H1
Pérez-Martini, L1
Blanco, RA1
Heffner, G1
Ordóñez-Comparini, R1
Javier, MA1
Noche, ML1
Sanchez, J1
Rivero, A1
Dal-Re, R2
Azanza, JR1
Riba, A1
Morell, F1

Reviews

7 reviews available for tulobuterol and Asthma

ArticleYear
[Clinical application of transdermal beta-2 agonists for the wheezing diseases in childhood].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2013, Volume: 51, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Bronchitis; Bronchodilator Agents; Child; Child, Presch

2013
Transdermal tulobuterol patch, a long-actingβ(2)-agonist.
    Allergology international : official journal of the Japanese Society of Allergology, 2012, Volume: 61, Issue:2

    Topics: Adrenergic beta-Agonists; Asthma; Bronchodilator Agents; Drug Approval; Evidence-Based Medicine; Hum

2012
[The brittle asthmatic and the morning dipper].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11

    Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Chromones; Circad

1996
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Administration, Cutaneous; Administration, Inhalation; Aminophylline; Androstadienes; Asthma; Eviden

2001
[Long-acting beta 2-stimulants].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenerg

2001
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2002, Volume: 122, Issue:1

    Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Asthma; Chronotherapy; Clinical Trials as Topic

2002
Tulobuterol in the management of obstructive airways disease in adults.
    Clinical therapeutics, 1985, Volume: 7, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Femal

1985

Trials

18 trials available for tulobuterol and Asthma

ArticleYear
[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2013, Volume: 15, Issue:6

    Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female;

2013
A 12-week, randomized, parallel-group, proof-of-concept study of tulobuterol patch and salmeterol inhaler as add-on therapy in adult-onset mild-to-moderate asthma.
    Clinical and experimental pharmacology & physiology, 2017, Volume: 44, Issue:1

    Topics: Adult; Aged; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hu

2017
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2009, Volume: 58, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Asthma;

2009
[Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment].
    Arerugi = [Allergy], 2012, Volume: 61, Issue:6

    Topics: Aged; Aged, 80 and over; Asthma; Biomarkers; Breath Tests; Bronchodilator Agents; Budesonide; Drug T

2012
Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years.
    Allergology international : official journal of the Japanese Society of Allergology, 2013, Volume: 62, Issue:1

    Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Asthma; Child; Child, Preschool; Female; Humans

2013
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:2

    Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Aged; Androstadiene

2004
Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.
    Arzneimittel-Forschung, 2004, Volume: 54, Issue:5

    Topics: Administration, Cutaneous; Adult; Anti-Asthmatic Agents; Asthma; Blood Proteins; Bronchial Hyperreac

2004
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:6

    Topics: Administration, Cutaneous; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Asthma; Be

2006
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2006, Volume: 43, Issue:7

    Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Inflammatory Agents

2006
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:11

    Topics: Administration, Cutaneous; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Femal

2006
[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:1

    Topics: Adrenergic beta-2 Receptor Antagonists; Adult; Asthma; Bronchodilator Agents; Female; Humans; Male;

2007
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:2

    Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albute

2007
Can a new beta 2-agonist reduce the mortality of asthma?
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albutero

1990
Effects of a combined treatment theophylline and tulobuterol on nocturnal chronic asthma.
    Lung, 1990, Volume: 168 Suppl

    Topics: Adrenergic beta-Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Admi

1990
Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Airway Resistance; Asthm

1990
Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies.
    The Journal of international medical research, 1986, Volume: 14, Issue:5

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Asthma; Child; Clinical Trials as Topic;

1986
Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:4

    Topics: Adult; Albuterol; Asthma; Drug Evaluation; Fenoterol; Humans; Middle Aged; Random Allocation; Respir

1988
Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma.
    British journal of clinical pharmacology, 1986, Volume: 21, Issue:2

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchodilator Agents; Clinical

1986

Other Studies

16 other studies available for tulobuterol and Asthma

ArticleYear
Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma.
    Journal of biomaterials science. Polymer edition, 2021, Volume: 32, Issue:4

    Topics: Animals; Asthma; Delayed-Action Preparations; Graphite; Hydrogels; Rabbits; Rats; Rats, Sprague-Dawl

2021
Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:9

    Topics: Adrenergic beta-Agonists; Adult; Asthma; Cough; Female; Humans; Japan; Male; Middle Aged; Prospectiv

2013
Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis.
    The Tohoku journal of experimental medicine, 2009, Volume: 218, Issue:4

    Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Animals; Asthma; Diaphragm; Disease Models, Ani

2009
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.
    Biological & pharmaceutical bulletin, 2010, Volume: 33, Issue:10

    Topics: Animals; Asthma; Bronchodilator Agents; Disease Models, Animal; Drugs, Generic; Female; Patents as T

2010
[Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2012, Volume: 132, Issue:5

    Topics: Aged; Asthma; Child, Preschool; Drug Substitution; Drug Utilization; Drugs, Generic; Female; Humans;

2012
Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.
    Clinical and experimental pharmacology & physiology, 2002, Volume: 29, Issue:12

    Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Animals; Asthma; Delayed-Action Preparations;

2002
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome.
    Allergy, 2003, Volume: 58, Issue:7

    Topics: Adrenergic beta-Agonists; Asthma; Churg-Strauss Syndrome; Cyclophosphamide; Drug Hypersensitivity; F

2003
Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy.
    Chronobiology international, 2005, Volume: 22, Issue:2

    Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Biologica

2005
[Airway hypersensitivity and beta-adrenergic blockade in asthmatic patients, with special reference to insulin response to beta-stimulant].
    Arerugi = [Allergy], 1983, Volume: 32, Issue:12

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Asthma; Blood Glucose; Cyclic

1983
Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:2

    Topics: Administration, Cutaneous; Adult; Aged; Asthma; Blood Pressure; Child; Female; Humans; Male; Respira

1995
[Effect of a patch formulation of tulobuterol on cough scores and PEF in patients with cough variant asthma].
    Arerugi = [Allergy], 2000, Volume: 49, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Asthma; Bronchodilator Agents; Cough; Drug Evaluation; Female; Huma

2000
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2001, Volume: 121, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Ch

2001
[Therapeutic aspects of intractable asthma].
    Nihon Kyobu Shikkan Gakkai zasshi, 1988, Volume: 26, Issue:3

    Topics: Adult; Aged; Asthma; Cromolyn Sodium; Female; Humans; Ketotifen; Male; Middle Aged; ortho-Aminobenzo

1988
[Pulmonary function tests in asthmatic children in treatment with tulobuterol].
    Boletin medico del Hospital Infantil de Mexico, 1989, Volume: 46, Issue:4

    Topics: Adolescent; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Flow Rates; Forced Expir

1989
Protective effect of tulobuterol on methacholine-induced bronchospasm in asthmatic children.
    European journal of clinical pharmacology, 1988, Volume: 35, Issue:1

    Topics: Adolescent; Asthma; Bronchial Spasm; Bronchodilator Agents; Child; Female; Forced Expiratory Volume;

1988
Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma.
    British journal of clinical pharmacology, 1985, Volume: 20, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Hemodynamics; Humans; Mid

1985